CN111630059B - 用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物 - Google Patents

用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物 Download PDF

Info

Publication number
CN111630059B
CN111630059B CN201880081367.7A CN201880081367A CN111630059B CN 111630059 B CN111630059 B CN 111630059B CN 201880081367 A CN201880081367 A CN 201880081367A CN 111630059 B CN111630059 B CN 111630059B
Authority
CN
China
Prior art keywords
psma
htk01169
htk
tumor
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880081367.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111630059A (zh
Inventor
林国贤
弗朗索瓦·伯纳德
郭修廷
张正兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Provincial Health Services Authority
Original Assignee
University of British Columbia
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Provincial Health Services Authority filed Critical University of British Columbia
Publication of CN111630059A publication Critical patent/CN111630059A/zh
Application granted granted Critical
Publication of CN111630059B publication Critical patent/CN111630059B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201880081367.7A 2017-10-22 2018-10-22 用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物 Active CN111630059B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575460P 2017-10-22 2017-10-22
US62/575,460 2017-10-22
PCT/CA2018/051336 WO2019075583A1 (en) 2017-10-22 2018-10-22 NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Publications (2)

Publication Number Publication Date
CN111630059A CN111630059A (zh) 2020-09-04
CN111630059B true CN111630059B (zh) 2025-06-06

Family

ID=66173073

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880081367.7A Active CN111630059B (zh) 2017-10-22 2018-10-22 用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物

Country Status (8)

Country Link
US (2) US20200339625A1 (https=)
EP (1) EP3700917A4 (https=)
JP (2) JP7282792B2 (https=)
KR (1) KR102884167B1 (https=)
CN (1) CN111630059B (https=)
AU (1) AU2018352731B2 (https=)
CA (1) CA3079906A1 (https=)
WO (1) WO2019075583A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
SG11202005511VA (en) 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020210909A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CN110317151B (zh) * 2019-06-06 2022-06-24 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
CA3174082A1 (en) * 2020-03-04 2021-09-10 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2022167681A1 (en) * 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
JP2024544870A (ja) * 2021-11-10 2024-12-05 スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN119855612A (zh) * 2022-09-09 2025-04-18 同宜医药（苏州）有限公司 放射性核素偶联药物及其药物组合物和应用
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215627A1 (en) * 2017-05-24 2018-11-29 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
EP3544960A1 (en) 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215627A1 (en) * 2017-05-24 2018-11-29 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile;Martina Benesova等;Molecular Pharmaceutics;第15卷(第03期);第934-946页 *
Preclinical Development of Novel PSMA- Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy;Christoph A. Umbricht等;Molecular Pharmaceutics;第15卷(第6期);第2297-2306页 *

Also Published As

Publication number Publication date
US20230348535A1 (en) 2023-11-02
JP2023113695A (ja) 2023-08-16
WO2019075583A1 (en) 2019-04-25
EP3700917A4 (en) 2021-08-04
CA3079906A1 (en) 2019-04-25
KR102884167B1 (ko) 2025-11-12
CN111630059A (zh) 2020-09-04
JP7282792B2 (ja) 2023-05-29
KR20200100043A (ko) 2020-08-25
EP3700917A1 (en) 2020-09-02
AU2018352731B2 (en) 2023-10-05
US20200339625A1 (en) 2020-10-29
AU2018352731A1 (en) 2020-05-21
JP7592120B2 (ja) 2024-11-29
JP2021503490A (ja) 2021-02-12

Similar Documents

Publication Publication Date Title
CN111630059B (zh) 用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物
US11951190B2 (en) Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
JP6814234B2 (ja) 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
ES2960729T3 (es) 177 Lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana
JP7805637B2 (ja) がんに対するペプチド受容体を標的とした放射性核種療法の治療性能を改善するための構造最適化法
JP2022549258A (ja) セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト
Ji et al. Evaluation of K (HYNIC) 2 as a bifunctional chelator for 99mTc-labeling of small biomolecules
US20250009911A1 (en) DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
JP2026506464A (ja) 部位特異的ｕＰＡＲ標的化のための放射性核種標識ペプチドコンジュゲート
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
Aranda Synthesis and radiolabelling of a hetero bivalent conjugate of bombesin and folic acid for the evaluation of the metabolic activity of breast cancer cells
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant